About us

Expertise in Biopharmaceutical Innovation

With a vision for a self-reliant Africa, we specialize in mRNA vaccines, oncology treatments, insulin, monoclonal antibodies, and generics, ensuring affordable and high-quality healthcare solutions.

$ 0 Billion+

USD Investment

0 Billion+

Vaccines Capacity

Who We Are

Dei Biopharma Ltd is realizing Africa’s aspiration for a self-reliant healthcare system. Established in Mattuga, Uganda, our $1.1 billion facility was inaugurated in 2021 by Presidents Yoweri Museveni and William Ruto.

Our Vision & Mission

Our Vision

To drive Africa's growth by creating business opportunities and delivering quality medicines through cutting-edge, innovative processes. We aspire to be the partner of choice for contract manufacturing and pharmaceutical branding, setting new standards in the industry.

Our Mission

To establish ourselves as a globally recognized pharmaceutical company, producing a diverse range of vaccines and affordable medicines to combat widespread diseases. We are committed to empowering Africa through innovation, research, advanced manufacturing, and technology-driven solutions.

Our Values

At Dei BioPharma, we are driven by a commitment to excellence in healthcare innovation. Our approach is rooted in a dedication to quality, safety, and global standards, ensuring that we deliver life-changing medicines and vaccines.

Accountability

We take responsibility for our actions and uphold the highest standards in all we do.

Integrity

We uphold honesty, transparency, and ethical practices in every aspect of our work.

Customer Focus

We prioritize our customers' needs, delivering high-quality and reliable healthcare solutions.

Innovation

We embrace cutting-edge research and technology to drive pharmaceutical advancements.

Teamwork

We foster collaboration and unity, working together to achieve impactful results.

Excellence

We are committed to delivering superior quality in medicines, vaccines, and healthcare solutions.

Key Milestones & Future Roadmap

Our roadmap highlights key milestones in regulatory approvals, production, and global expansion, driving pharmaceutical excellence.

Production Started

Manufacturing operations commenced, marking the beginning of large-scale pharmaceutical production.

2024
Regulatory Approval for the Plant/Manufacturing Unit

Securing certification for compliance with global quality and safety standards.

January 2025
Regulatory Approval for the Products

Gaining official authorization to distribute and commercialize medicines and vaccines.

March – April 2025
Commercial Launch in Uganda

Introducing high-quality pharmaceuticals to the Ugandan market.

April 2025
Product Registration Initiation with US-FDA, EU (EMA) & WHO

Advancing towards global regulatory approvals for international distribution.

2nd Quarter of 2025
Commercial Launch in EAC

Expanding operations to serve the East African Community (EAC) region.

2nd - 3rd Quarter of 2025
Commercial Launch in SADC

Entering the Southern African Development Community (SADC) pharmaceutical market.

3rd - 4th Quarter of 2025
Commercial Launch in Rest of Sub-Saharan Africa

Scaling up to provide medicines across Sub-Saharan Africa.

1st Quarter of 2026
Commercial Launch in US-FDA, EU (EMA) & WHO

Achieving global market entry with internationally approved pharmaceutical products.

2nd - 3rd Quarter of 2026

Our Leadership Team

Our leadership team combines decades of pharmaceuticals, biotechnology, and global healthcare expertise. Together, they lead DEI BioPharma in its mission to redefine healthcare for the better

View All